[Lilly’s GLP-1 Direct-To-Consumer Move, Changes The “Game Changer” Game](https://wbbsec.com/opinions-and-features/lillys-glp-1-direct-to-consumer-move-changes-the-game-changer-game/)
[Lilly’s GLP-1 Direct-To-Consumer Move, Changes The “Game Changer” Game](https://wbbsec.com/opinions-and-features/lillys-glp-1-direct-to-consumer-move-changes-the-game-changer-game/)
powered by bulletin
In: Opinions & Features

1.4.2024 | Forbes

By Steve Brozak

“Game changer” refers to any simple solution paraded as the answer to a complex problem. The ubiquitous use of game changer in describing the benefits of the GLP-1 category of drugs is the latest example. The pharmaceutical giant, Eli Lilly has just launched its newly approved GLP-1 product, Zepbound™ in a direct-to-consumer approach on its Lilly Direct™. This marketing move is potentially quite problematic.

These drugs were originally developed to have a positive effect on Type 2 diabetes (T2D). The latest game changing pronouncement is their use for weight loss. They are also being hailed as a cure for heart disease, worn hips and degenerated knees. There’s even a peer reviewed study that says they can treat acne!

GLP-1 drugs have many functions. They stimulate glucose-dependent insulin release from the pancreas, slow gastric emptying (prolonging a feeling of satiety), inhibit post-meal glucagon release (glucagon stimulates liver and muscle cells to convert stored glycogen back into glucose, raising blood glucose levels), and reduce the desire for food intake. Lower caloric intake means less fat production. Less fat correlates with lower blood glucose levels, fewer heart attacks, less weight on aging hip and knee joints, improvement in fatty liver disease, delayed progression of diabetes-related kidney disease, and more energy for day-to-day activities.

To read the entire article on Forbes, please click here…